Nasdaq · CIK 0001590560
QURE uniQure N.V.
Insider trading from SEC Form 4. Last filing Mar 6, 2026. Close $22.59 on Oct 9, 2026, +150% from the 52-week low and -68% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
QUREOct 9, 2026 · close 22.59
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at uniQure N.V., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Walid Abi-Saab Chief Medical Officer sell | $7,320 808 shares | -0% | +8% from low-87% from high | |
| 47Moderate | Christian Klemt Chief Financial Officer sell | $109k 12,000 shares | -5% | +8% from low-87% from high | |
| 51Moderate | Matthew C Kapusta CEO, Managing Director sell | $132k 14,581 shares | -2% | +8% from low-87% from high | |
| 30Weak | Walid Abi-Saab Chief Medical Officer sell | $17k 1,660 shares | -1% | +26% from low-85% from high | |
| 47Moderate | Christian Klemt Chief Financial Officer sell | $125k 12,532 shares | -6% | +26% from low-85% from high | |
| 55Moderate | Matthew C Kapusta CEO, Managing Director sell | $343k 34,437 shares | -5% | +26% from low-85% from high | |
| 48Moderate | Christian Klemt Chief Financial Officer sell | $148k 6,217 shares | -3% | +198% from low-65% from high | |
| 54Moderate | Matthew C Kapusta CEO, Managing Director sell | $295k 12,378 shares | -2% | +198% from low-65% from high | |
| 18Weak | Robert Gut director sell | $630k 25,613 shares | -44% | +176% from low-67% from high | |
| 4Weak | Jack Kaye director sell | $174k 6,390 shares | -24% | +204% from low-64% from high | |
| 21Weak | Robert Gut director sell | $857k 31,434 shares | -44% | +383% from low-61% from high | |
| 33Weak | Jack Kaye director sell | $1.2M 38,810 shares | -128% | +447% from low-57% from high | |
| 19Weak | Christian Klemt Chief Financial Officer sell | $945k 18,000 shares | -8% | +946% from low0% from high | |
| 33Weak | Matthew C Kapusta CEO, Managing Director sell | $9.4M 226,316 shares | -26% | +946% from low0% from high | |
| 30Weak | Walid Abi-Saab Chief Medical Officer sell | $20k 1,466 shares | -1% | +205% from low-23% from high | |
| 35Weak | Madhavan Balachandran director sell | $31k 2,112 shares | -5% | +213% from low-21% from high | |
| 37Weak | Robert Gut director sell | $48k 3,336 shares | -6% | +213% from low-21% from high | |
| 35Weak | Rachelle Suzanne Jacques director sell | $31k 2,112 shares | -7% | +213% from low-21% from high | |
| 35Weak | Jack Kaye director sell | $31k 2,112 shares | -9% | +213% from low-21% from high | |
| 35Weak | David D. Meek director sell | $31k 2,112 shares | -6% | +213% from low-21% from high | |
| 35Weak | Leonard E Post director sell | $31k 2,112 shares | -7% | +213% from low-21% from high | |
| 35Weak | Jeremy P. Springhorn director sell | $31k 2,112 shares | -5% | +213% from low-21% from high | |
| 38Weak | Jeannette Potts Chief Legal Officer sell | $71k 4,670 shares | -4% | +233% from low-16% from high | |
| 30Weak | Walid Abi-Saab Chief Medical Officer sell | $14k 1,350 shares | -1% | - | |
| 47Moderate | Christian Klemt Chief Financial Officer sell | $107k 10,438 shares | -5% | - | |
| 54Moderate | Matthew C Kapusta CEO, Managing Director sell | $292k 28,341 shares | -4% | - | |
| 54Moderate | Christian Klemt Chief Financial Officer sell | $186k 17,257 shares | -10% | - | |
| 55Moderate | Matthew C Kapusta CEO, Managing Director sell | $362k 33,444 shares | -6% | - | |
| 28Weak | Matthew C Kapusta CEO, Managing Director sell | $1.5M 100,000 shares | -14% | - | |
| 30Weak | Christian Klemt Chief Financial Officer sell | $14k 1,796 shares | -1% | - | |
| 38Weak | Matthew C Kapusta CEO, Managing Director sell | $26k 3,418 shares | -1% | - |
Transactions
The last 95 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | Walid Abi-Saab Chief Medical Officer | AGrant or award Ordinary Shares | +41,700 | $0.00 | $0 | 190,477 | Mar 6, 2026 |
| Mar 4, 2026 | Christian Klemt Chief Financial Officer | AGrant or award Ordinary Shares | +39,600 | $0.00 | $0 | 238,581 | Mar 6, 2026 |
| Mar 4, 2026 | Matthew C Kapusta CEO, Managing Director | AGrant or award Ordinary Shares | +70,600 | $0.00 | $0 | 675,239 | Mar 6, 2026 |
| Mar 4, 2026 | Walid Abi-Saab Chief Medical Officer | SOpen-market sale Ordinary Shares | -808 | $9.06 | $7,320 | 189,669 | Mar 6, 2026 |
| Mar 4, 2026 | Matthew C Kapusta CEO, Managing Director | SOpen-market sale Ordinary Shares | -14,581 | $9.06 | $132k | 660,658 | Mar 6, 2026 |
| Mar 4, 2026 | Christian Klemt Chief Financial Officer | SOpen-market sale Ordinary Shares | -12,000 | $9.06 | $109k | 226,581 | Mar 6, 2026 |
| Mar 4, 2026 | Christian Klemt Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +63,900 | $0.00 | $0 | 63,900 | Mar 6, 2026 |
| Mar 4, 2026 | Matthew C Kapusta CEO, Managing Director | AGrant or award Stock Option (Right to Buy)derivative | +113,800 | $0.00 | $0 | 113,800 | Mar 6, 2026 |
| Mar 4, 2026 | Walid Abi-Saab Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +67,200 | $0.00 | $0 | 67,200 | Mar 6, 2026 |
| Mar 2, 2026 | Walid Abi-Saab Chief Medical Officer | SOpen-market sale Ordinary Shares | -1,660 | $9.95 | $17k | 148,777 | Mar 4, 2026 |
| Mar 2, 2026 | Christian Klemt Chief Financial Officer | SOpen-market sale Ordinary Shares | -12,532 | $9.95 | $125k | 198,981 | Mar 4, 2026 |
| Mar 2, 2026 | Matthew C Kapusta CEO, Managing Director | SOpen-market sale Ordinary Shares | -34,437 | $9.95 | $343k | 604,639 | Mar 4, 2026 |
| Feb 25, 2026 | Christian Klemt Chief Financial Officer | SOpen-market sale Ordinary Shares | -6,217 | $23.86 | $148k | 211,513 | Feb 27, 2026 |
| Feb 25, 2026 | Matthew C Kapusta CEO, Managing Director | SOpen-market sale Ordinary Shares | -12,378 | $23.86 | $295k | 639,076 | Feb 27, 2026 |
| Jan 12, 2026 | Robert Gut director | MOption exercise Ordinary Shares10b5-1 | +17,810 | $14.08 | $251k | 57,955 | Jan 14, 2026 |
| Jan 12, 2026 | Robert Gut director | SOpen-market sale Ordinary Shares10b5-1 | -17,310 | $24.39 | $422k | 40,645 | Jan 14, 2026 |
| Jan 12, 2026 | Robert Gut director | SOpen-market sale Ordinary Shares10b5-1 | -500 | $25.03 | $13k | 40,145 | Jan 14, 2026 |
| Jan 12, 2026 | Robert Gut director | SOpen-market sale Ordinary Shares10b5-1 | -7,803 | $25.09 | $196k | 32,342 | Jan 14, 2026 |
| Jan 12, 2026 | Robert Gut director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -17,810 | $0.00 | $0 | 0 | Jan 14, 2026 |
| Jan 9, 2026 | Jack Kaye director | MOption exercise Ordinary Shares10b5-1 | +6,390 | $19.39 | $124k | 26,829 | Jan 12, 2026 |
| Jan 9, 2026 | Jack Kaye director | SOpen-market sale Ordinary Shares10b5-1 | -6,390 | $27.28 | $174k | 20,439 | Jan 12, 2026 |
| Jan 9, 2026 | Jack Kaye director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,390 | $0.00 | $0 | 0 | Jan 12, 2026 |
| Nov 6, 2025 | Robert Gut director | MOption exercise Ordinary Shares10b5-1 | +15,840 | $4.57 | $72k | 71,579 | Nov 10, 2025 |
| Nov 6, 2025 | Robert Gut director | SOpen-market sale Ordinary Shares10b5-1 | -15,840 | $27.22 | $431k | 55,739 | Nov 10, 2025 |
| Nov 6, 2025 | Robert Gut director | SOpen-market sale Ordinary Shares10b5-1 | -15,594 | $27.30 | $426k | 40,145 | Nov 10, 2025 |
| Nov 6, 2025 | Robert Gut director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -15,840 | $0.00 | $0 | 0 | Nov 10, 2025 |
| Nov 4, 2025 | Jack Kaye director | MOption exercise Ordinary Shares10b5-1 | +10,000 | $7.37 | $74k | 30,439 | Nov 6, 2025 |
| Nov 4, 2025 | Jack Kaye director | SOpen-market sale Ordinary Shares10b5-1 | -10,000 | $30.36 | $304k | 20,439 | Nov 6, 2025 |
| Nov 4, 2025 | Jack Kaye director | MOption exercise Ordinary Shares10b5-1 | +11,000 | $5.37 | $59k | 31,439 | Nov 6, 2025 |
| Nov 4, 2025 | Jack Kaye director | SOpen-market sale Ordinary Shares10b5-1 | -11,000 | $30.34 | $334k | 20,439 | Nov 6, 2025 |
| Nov 4, 2025 | Jack Kaye director | MOption exercise Ordinary Shares10b5-1 | +17,810 | $14.08 | $251k | 38,249 | Nov 6, 2025 |
| Nov 4, 2025 | Jack Kaye director | SOpen-market sale Ordinary Shares10b5-1 | -17,810 | $30.33 | $540k | 20,439 | Nov 6, 2025 |
| Nov 4, 2025 | Jack Kaye director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 0 | Nov 6, 2025 |
| Nov 4, 2025 | Jack Kaye director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -11,000 | $0.00 | $0 | 0 | Nov 6, 2025 |
| Nov 4, 2025 | Jack Kaye director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -17,810 | $0.00 | $0 | 0 | Nov 6, 2025 |
| Sep 24, 2025 | Christian Klemt Chief Financial Officer | MOption exercise Ordinary Shares10b5-1 | +3,000 | $13.03 | $39k | 220,730 | Sep 26, 2025 |
| Sep 24, 2025 | Matthew C Kapusta CEO, Managing Director | MOption exercise Ordinary Shares10b5-1 | +51,316 | $7.53 | $386k | 702,770 | Sep 26, 2025 |
| Sep 24, 2025 | Christian Klemt Chief Financial Officer | SOpen-market sale Ordinary Shares10b5-1 | -3,000 | $40.04 | $120k | 217,730 | Sep 26, 2025 |
| Sep 24, 2025 | Matthew C Kapusta CEO, Managing Director | MOption exercise Ordinary Shares10b5-1 | +175,000 | $6.22 | $1.1M | 877,770 | Sep 26, 2025 |
| Sep 26, 2025 | Christian Klemt Chief Financial Officer | MOption exercise Ordinary Shares10b5-1 | +15,000 | $5.37 | $81k | 232,730 | Sep 26, 2025 |
| Sep 24, 2025 | Matthew C Kapusta CEO, Managing Director | SOpen-market sale Ordinary Shares10b5-1 | -51,316 | $39.59 | $2.0M | 826,454 | Sep 26, 2025 |
| Sep 26, 2025 | Christian Klemt Chief Financial Officer | SOpen-market sale Ordinary Shares10b5-1 | -15,000 | $55.00 | $825k | 217,730 | Sep 26, 2025 |
| Sep 24, 2025 | Matthew C Kapusta CEO, Managing Director | SOpen-market sale Ordinary Shares10b5-1 | -60,000 | $40.04 | $2.4M | 766,454 | Sep 26, 2025 |
| Sep 24, 2025 | Christian Klemt Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,000 | $0.00 | $0 | 0 | Sep 26, 2025 |
| Sep 24, 2025 | Matthew C Kapusta CEO, Managing Director | SOpen-market sale Ordinary Shares10b5-1 | -49,978 | $40.68 | $2.0M | 716,476 | Sep 26, 2025 |
| Sep 26, 2025 | Christian Klemt Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 0 | Sep 26, 2025 |
| Sep 24, 2025 | Matthew C Kapusta CEO, Managing Director | SOpen-market sale Ordinary Shares10b5-1 | -5,022 | $41.69 | $209k | 711,454 | Sep 26, 2025 |
| Sep 24, 2025 | Matthew C Kapusta CEO, Managing Director | SOpen-market sale Ordinary Shares10b5-1 | -60,000 | $45.10 | $2.7M | 651,454 | Sep 26, 2025 |
| Sep 24, 2025 | Matthew C Kapusta CEO, Managing Director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -51,316 | $0.00 | $0 | 0 | Sep 26, 2025 |
| Sep 24, 2025 | Matthew C Kapusta CEO, Managing Director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -175,000 | $0.00 | $0 | 0 | Sep 26, 2025 |
| Jun 27, 2025 | Walid Abi-Saab Chief Medical Officer | SOpen-market sale Ordinary Shares | -1,466 | $13.92 | $20k | 150,437 | Jul 1, 2025 |
| Jun 20, 2025 | Madhavan Balachandran director | SOpen-market sale Ordinary Shares | -2,112 | $14.45 | $31k | 37,697 | Jun 24, 2025 |
| Jun 20, 2025 | Robert Gut director | SOpen-market sale Ordinary Shares | -3,336 | $14.45 | $48k | 56,879 | Jun 24, 2025 |
| Jun 20, 2025 | Rachelle Suzanne Jacques director | SOpen-market sale Ordinary Shares | -2,112 | $14.45 | $31k | 28,346 | Jun 24, 2025 |
| Jun 20, 2025 | Jack Kaye director | SOpen-market sale Ordinary Shares | -2,112 | $14.45 | $31k | 20,439 | Jun 24, 2025 |
| Jun 20, 2025 | David D. Meek director | SOpen-market sale Ordinary Shares | -2,112 | $14.45 | $31k | 34,190 | Jun 24, 2025 |
| Jun 20, 2025 | Leonard E Post director | SOpen-market sale Ordinary Shares | -2,112 | $14.45 | $31k | 29,937 | Jun 24, 2025 |
| Jun 20, 2025 | Jeremy P. Springhorn director | SOpen-market sale Ordinary Shares | -2,112 | $14.45 | $31k | 37,694 | Jun 24, 2025 |
| Jun 16, 2025 | Jeannette Potts Chief Legal Officer | SOpen-market sale Ordinary Shares | -4,670 | $15.14 | $71k | 115,073 | Jun 20, 2025 |
| Jun 11, 2025 | Jeremy P. Springhorn director | AGrant or award Ordinary Shares | +7,970 | $0.00 | $0 | 39,806 | Jun 13, 2025 |
| Jun 11, 2025 | Leonard E Post director | AGrant or award Ordinary Shares | +7,970 | $0.00 | $0 | 32,049 | Jun 13, 2025 |
| Jun 11, 2025 | David D. Meek director | AGrant or award Ordinary Shares | +7,970 | $0.00 | $0 | 36,302 | Jun 13, 2025 |
| Jun 11, 2025 | Jack Kaye director | AGrant or award Ordinary Shares | +7,970 | $0.00 | $0 | 22,551 | Jun 13, 2025 |
| Jun 11, 2025 | Rachelle Suzanne Jacques director | AGrant or award Ordinary Shares | +7,970 | $0.00 | $0 | 30,458 | Jun 13, 2025 |
| Jun 11, 2025 | Madhavan Balachandran director | AGrant or award Ordinary Shares | +7,970 | $0.00 | $0 | 39,809 | Jun 13, 2025 |
| Jun 11, 2025 | Robert Gut director | AGrant or award Ordinary Shares | +7,970 | $0.00 | $0 | 60,215 | Jun 13, 2025 |
| Jun 11, 2025 | Rachelle Suzanne Jacques director | AGrant or award Stock Option (Right to Buy)derivative | +15,630 | $0.00 | $0 | 15,630 | Jun 13, 2025 |
| Jun 11, 2025 | Jeremy P. Springhorn director | AGrant or award Stock Option (Right to Buy)derivative | +15,630 | $0.00 | $0 | 15,630 | Jun 13, 2025 |
| Jun 11, 2025 | Leonard E Post director | AGrant or award Stock Option (Right to Buy)derivative | +15,630 | $0.00 | $0 | 15,630 | Jun 13, 2025 |
| Jun 11, 2025 | Madhavan Balachandran director | AGrant or award Stock Option (Right to Buy)derivative | +15,630 | $0.00 | $0 | 15,630 | Jun 13, 2025 |
| Jun 11, 2025 | David D. Meek director | AGrant or award Stock Option (Right to Buy)derivative | +15,630 | $0.00 | $0 | 15,630 | Jun 13, 2025 |
| Jun 11, 2025 | Jack Kaye director | AGrant or award Stock Option (Right to Buy)derivative | +15,630 | $0.00 | $0 | 15,630 | Jun 13, 2025 |
| Jun 11, 2025 | Robert Gut director | AGrant or award Stock Option (Right to Buy)derivative | +15,630 | $0.00 | $0 | 15,630 | Jun 13, 2025 |
| Mar 3, 2025 | Walid Abi-Saab Chief Medical Officer | AGrant or award Ordinary Shares | +38,000 | $0.00 | $0 | 153,253 | Mar 5, 2025 |
| Mar 3, 2025 | Christian Klemt Chief Financial Officer | AGrant or award Ordinary Shares | +73,000 | $0.00 | $0 | 228,168 | Mar 5, 2025 |
| Mar 3, 2025 | Matthew C Kapusta CEO, Managing Director | AGrant or award Ordinary Shares | +99,000 | $0.00 | $0 | 679,795 | Mar 5, 2025 |
| Mar 4, 2025 | Walid Abi-Saab Chief Medical Officer | SOpen-market sale Ordinary Shares | -1,350 | $10.29 | $14k | 151,903 | Mar 5, 2025 |
| Mar 4, 2025 | Christian Klemt Chief Financial Officer | SOpen-market sale Ordinary Shares | -10,438 | $10.29 | $107k | 217,730 | Mar 5, 2025 |
| Mar 4, 2025 | Matthew C Kapusta CEO, Managing Director | SOpen-market sale Ordinary Shares | -28,341 | $10.29 | $292k | 651,454 | Mar 5, 2025 |
| Mar 3, 2025 | Matthew C Kapusta CEO, Managing Director | AGrant or award Stock Option (Right to Buy)derivative | +171,000 | $0.00 | $0 | 171,000 | Mar 5, 2025 |
| Mar 3, 2025 | Christian Klemt Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +126,000 | $0.00 | $0 | 126,000 | Mar 5, 2025 |
| Mar 3, 2025 | Walid Abi-Saab Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +66,000 | $0.00 | $0 | 66,000 | Mar 5, 2025 |
| Feb 25, 2025 | Christian Klemt Chief Financial Officer | SOpen-market sale Ordinary Shares | -14,341 | $10.70 | $153k | 152,372 | Feb 27, 2025 |
| Feb 25, 2025 | Matthew C Kapusta CEO, Managing Director | SOpen-market sale Ordinary Shares | -26,727 | $10.70 | $286k | 571,188 | Feb 27, 2025 |
| Feb 26, 2025 | Christian Klemt Chief Financial Officer | AGrant or award Ordinary Shares | +5,712 | $0.00 | $0 | 158,084 | Feb 27, 2025 |
| Feb 26, 2025 | Matthew C Kapusta CEO, Managing Director | AGrant or award Ordinary Shares | +16,324 | $0.00 | $0 | 587,512 | Feb 27, 2025 |
| Feb 27, 2025 | Christian Klemt Chief Financial Officer | SOpen-market sale Ordinary Shares | -2,916 | $11.32 | $33k | 155,168 | Feb 27, 2025 |
| Feb 27, 2025 | Matthew C Kapusta CEO, Managing Director | SOpen-market sale Ordinary Shares | -6,717 | $11.32 | $76k | 580,795 | Feb 27, 2025 |
| Dec 10, 2024 | Matthew C Kapusta CEO, Managing Director | MOption exercise Ordinary Shares10b5-1 | +100,000 | $14.71 | $1.5M | 697,915 | Dec 12, 2024 |
| Dec 10, 2024 | Matthew C Kapusta CEO, Managing Director | SOpen-market sale Ordinary Shares10b5-1 | -100,000 | $15.03 | $1.5M | 597,915 | Dec 12, 2024 |
| Dec 10, 2024 | Matthew C Kapusta CEO, Managing Director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -100,000 | $0.00 | $0 | 0 | Dec 12, 2024 |
| Dec 8, 2024 | Christian Klemt Chief Financial Officer | AGrant or award Ordinary Shares | +3,672 | $0.00 | $0 | 168,509 | Dec 10, 2024 |
| Dec 8, 2024 | Matthew C Kapusta CEO, Managing Director | AGrant or award Ordinary Shares | +10,494 | $0.00 | $0 | 601,333 | Dec 10, 2024 |
| Dec 9, 2024 | Christian Klemt Chief Financial Officer | SOpen-market sale Ordinary Shares | -1,796 | $7.55 | $14k | 166,713 | Dec 10, 2024 |
| Dec 9, 2024 | Matthew C Kapusta CEO, Managing Director | SOpen-market sale Ordinary Shares | -3,418 | $7.63 | $26k | 597,915 | Dec 10, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Walid Abi-SaabChief Medical Officer
- Madhavan Balachandrandirector
- Robert Gutdirector
- Rachelle Suzanne Jacquesdirector
- Christian KlemtChief Financial Officer
- Matthew C KapustaCEO, Managing Director
- Jack Kayedirector
- David D. Meekdirector
- Leonard E Postdirector
- Jeannette PottsChief Legal Officer
- Jeremy P. Springhorndirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.